erleada
janssen-cilag international nv - apalutamide - prostatične neoplazme - endokrini terapija - erleada je navedeno:pri odraslih moških za zdravljenje brez metastatskim kastracije odporne raka prostate (nmcrpc), ki so na visoko tveganje za razvoj bolezni metastatskim. pri odraslih moških za zdravljenje metastatskega hormonsko občutljivih raka prostate (mhspc) v kombinaciji z androgen odvzem terapija (adt).
nuceiva
evolus pharma b.v. - botulinum toksin tipa a - staranje kože - drugih mišičnih relaksantov, peripherally, ki delujejo agenti - začasno izboljšanje izgleda zmerno do hudo navpične črte med obrvi videl na najvišji jezijo (glabellar linij), ko resnost nad obrazne linije je pomemben psihološki vpliv pri odraslih pod 65 let starosti.
daurismo
pfizer europe ma eeig - glasdegib maleate - leukemija, myeloid, akutna - antineoplastična sredstva - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastična sredstva - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
evrysdi
roche registration gmbh - risdiplam - mišična atrofija, hrbtenica - druga zdravila za motnje mišično-skeletnega sistema - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.
retsevmo
eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastična sredstva - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.
dysport 300 enot prašek za raztopino za injiciranje
botulinski toksin tipa a - prašek za raztopino za injiciranje - botulinski toksin tipa a 300 e. / 1 viala - botulinski toksin
eprocliv 50 mg/1000 mg filmsko obložene tablete
metformin; sitagliptin - filmsko obložena tableta - metformin 780 mg / 1 tableta sitagliptin50 mg / 1 tableta; sitagliptin 50 mg / 1 tableta - metformin in sitagliptin
maymetsi 50 mg/850 mg filmsko obložene tablete
metformin; sitagliptin - filmsko obložena tableta - metformin 662,9 mg / 1 tableta sitagliptin50 mg / 1 tableta; sitagliptin 50 mg / 1 tableta - metformin in sitagliptin
maymetsi 50 mg/850 mg filmsko obložene tablete
metformin; sitagliptin - filmsko obložena tableta - metformin 662,9 mg / 1 tableta sitagliptin50 mg / 1 tableta; sitagliptin 50 mg / 1 tableta - metformin in sitagliptin